$ACST The post hoc study will NO doubt reveal what happened to the placebo arm. A fellow investor stated that though statins, if prescribed by error to the placebo arm at start of study, can show TG reductions, it's impossible to increase plasma EPA levels and RBC (red blood cell) counts. Thus Acasti will be able to clearly show what happened. Now he f they can prove it clearly was only those 5 sites (36% of patients in T1) then they will hit statistical significance in T2 (12% of patients in T2). This stock is heavily held by retail investors until data is released. Thus the spike last week waiting for really nothing (FDA remarks) and subsequent down draft. Institutional investors have plenty of time and patience to scoop up scared retail investors and those running for the door with any good news. Science always wins.